Should Dermatologists Recommend Direct‐to‐Consumer App‐Based Remote Diagnostics? An Ethical Analysis

ABSTRACT Background Dermatology patients still face barriers in accessing timely specialist care. As direct‐to‐consumer (DTC) apps for remote dermatological diagnostics proliferate, guidance is lacking. While promising efficiency and efficacy, their clinical—and ethical—legitimacy is not yet well established. Objectives We aim to provide a comprehensive ethical analysis as an approach to structuring the field and to aid ethically grounded recommendations to patients. Methods We applied a structured ethical analysis, as suggested by Marckmann, with (1) scenario description, (2) definition of normative criteria, (3) criterion‐wise assessment of all data, (4) synthesis of evaluations, and (5) practical recommendations, to systematically examine DTC dermatology apps through the lens of five bioethical/AI ethics principles: autonomy, beneficence, non‐maleficence, justice, and explicability. Results Our analysis highlights that DTC apps may be endorsed in specific, rigorously vetted cases. Key conditions include formal regulatory approval, compliance with data protection standards, and provision of medically sound, transparent, and comprehensible outputs that must never undermine the standard of care, the integrity of health systems, or the trust‐based patient–physician relationship. In scenarios such as skin cancer detection, where AI performance is particularly strong, apps leveraging suitable models hold potential for ethical justification for standardized use, given their potential to bridge care gaps, reduce unnecessary referrals and harm, provided that bias is mitigated via robust dataset inclusion of marginalized groups and ongoing performance monitoring. Conclusions We advocate a blended‐care model: apps are appropriate for monitoring and follow‐up, while initial diagnostics remain under professional oversight. As AI evolves, Human‐in‐the‐Loop systems offer a morally tenable path in areas of diagnostic uncertainty. Throughout, clinicians must remain vigilant of app limitations and inform patients of risk. Our ethical framework and recommendations aim to support the responsible augmentation of dermatologic practice with rapidly evolving DTC tools.